Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02001571 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function
A Phase 1 study, sponsored by Cougar Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02001571 is a Phase 1 study that has completed, run by Cougar Biotechnology. The registered enrollment target is 24 participants.
The verdict
NCT02001571, a Phase 1 study, has completed, sponsored by Cougar Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and pharmacokinetics (study of what the body does to a drug) of 1000 mg oral dose of abiraterone acetate and its major metabolite(s) with mild or moderate hepatic impairment and matched control Participants with normal hepatic function.
Interventions
- DRUG Abiraterone acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02001571
The ClinicalTrials.gov registry entry for NCT02001571 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cougar Biotechnology, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abiraterone acetate is the first listed.
NCT02001571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02001571 about?
NCT02001571 is a clinical study titled "A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function". The purpose of this study is to evaluate the safety and pharmacokinetics (study of what the body does to a drug) of 1000 mg oral dose of abiraterone acetate and its major metabolite(s) with mild or moderate hepatic impairment and matched control Participants with normal hepatic function.
What is the current status of trial NCT02001571?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2009-08. Estimated completion is 2010-04.
What interventions are being tested in trial NCT02001571?
The interventions under investigation include: Abiraterone acetate (DRUG).
Who is sponsoring clinical trial NCT02001571?
This trial is sponsored by Cougar Biotechnology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.